Share Price | Mabwell (Shanghai) Bioscience Co., Ltd. Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor Management Efficiency with a low ROCE of 0%

The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward

High Debt Company with a Debt to Equity ratio (avg) at times

Poor long term growth as Net Sales has grown by an annual rate of 100.64% and Operating profit at -18.67% over the last 5 years

The company has declared Negative results for the last 4 consecutive quarters

Risky -

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CNY 8,052 Million (Large Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

1.25

Return on Equity

-124.91%

Price to Book

10.58

Revenue and Profits:

Net Sales:

54 Million

(Quarterly Results - Jun 2025)

Net Profit:

-260 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-12.81%

6 Months

11.2%

1 Year

124.15%

2 Years

39.63%

3 Years

93.98%

4 Years

70.72%

5 Years

0.0%

Mabwell (Shanghai) Bioscience Co., Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Mabwell (Shanghai) Bioscience Co., Ltd. Reports Strong Financial Performance in Q1 2025

Mabwell (Shanghai) Bioscience Co., Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has showcased a robust financial performance for the quarter ending March 2025. The company's net sales for the first nine months have reached CNY 122.8 MM, reflecting a significant growth rate of 19.94% compared to the previous year.

In addition to impressive sales figures, Mabwell has reported a higher net profit for the half-year period, amounting to CNY -641.86 MM. This indicates a positive trend in the company's financial health, despite the challenges faced in the industry.

Another noteworthy aspect of Mabwell's financial results is the substantial decrease in raw material costs, which have fallen by 67.28% year-over-year. This reduction is expected to enhance the company's profitability and operational efficiency moving forwar...

Read full news article

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

100.64%

EBIT Growth (5y)

-18.67%

EBIT to Interest (avg)

-92.39

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.87

Sales to Capital Employed (avg)

0.06

Tax Ratio

0.08%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

12.40

EV to EBIT

-9.91

EV to EBITDA

-11.86

EV to Capital Employed

6.11

EV to Sales

63.24

PEG Ratio

Dividend Yield

ROCE (Latest)

-61.68%

ROE (Latest)

-140.93%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 24.13% vs -22.06% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 11.18% vs 16.55% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "53.50",
          "val2": "43.10",
          "chgp": "24.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-206.80",
          "val2": "-222.50",
          "chgp": "7.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "20.50",
          "val2": "18.80",
          "chgp": "9.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-259.80",
          "val2": "-292.50",
          "chgp": "11.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-4,888.30%",
          "val2": "-6,430.60%",
          "chgp": "154.23%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 56.21% vs 380.62% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 1.15% vs -10.51% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "193.70",
          "val2": "124.00",
          "chgp": "56.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-884.80",
          "val2": "-978.50",
          "chgp": "9.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "57.90",
          "val2": "13.50",
          "chgp": "328.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.50",
          "val2": "-6.60",
          "chgp": "107.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1,046.60",
          "val2": "-1,058.80",
          "chgp": "1.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-5,322.10%",
          "val2": "-8,771.50%",
          "chgp": "344.94%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

53.50

43.10

24.13%

Operating Profit (PBDIT) excl Other Income

-206.80

-222.50

7.06%

Interest

20.50

18.80

9.04%

Exceptional Items

0.00

Consolidate Net Profit

-259.80

-292.50

11.18%

Operating Profit Margin (Excl OI)

-4,888.30%

-6,430.60%

154.23%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 24.13% vs -22.06% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 11.18% vs 16.55% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

193.70

124.00

56.21%

Operating Profit (PBDIT) excl Other Income

-884.80

-978.50

9.58%

Interest

57.90

13.50

328.89%

Exceptional Items

0.50

-6.60

107.58%

Consolidate Net Profit

-1,046.60

-1,058.80

1.15%

Operating Profit Margin (Excl OI)

-5,322.10%

-8,771.50%

344.94%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 56.21% vs 380.62% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 1.15% vs -10.51% in Dec 2023

All Annual Results

Company CV

About Mabwell (Shanghai) Bioscience Co., Ltd.

Mabwell (Shanghai) Bioscience Co., Ltd.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available